"In response to a question about the applicability of her mouse model to humans, she noted Listeria also infects human pancreatic cancer cells and myeloid-derived suppressor cells, which helps to deliver the Listeria to the tumor microenvironment. Also, in humans the tumor microenvironment – but not normal tissues – is heavily immune suppressed, which is necessary for the Listeria to survive. Furthermore, both Listeria and 188Rhenium have already been tested in human clinical trials, and both induced only very mild side effects. “Therefore, we believe that the radioactive Listeria is applicable to humans."
“We would like to apply our treatment of radioactive Listeria as an early second line therapy directly after surgery for the primary tumor, to eliminate existing metastases and to prevent new metastases, and to eliminate any remaining tumor cells of the primary tumors.”
In an ideal world, we would like to know how to prevent pancreatic cancer in the first place, and research into prevention, which has recently been the focus of lobbying in Congress, may still yield valuable discoveries in the future.
In the meantime, however, if the radioactive Listeria approach to destroying metastases from pancreatic cancer proves safe and effective in humans, it would represent a huge advance in our ability to combat this most fatal cancer.
If that’s the best we can have for the present, we’ll take it."